C-reactive protein as a biomarker of emergent osteoarthritis.

OBJECTIVE We evaluated C-reactive protein (C-RP), a quantitative marker of the acute phase response, as a potential biomarker of prevalent and incident osteoarthritis of the knee (OAK). METHODS Serum C-reactive protein concentrations were characterized with ultrasensitive rate nephelometry in a population-based sample of 1025 women (318 African-American and 707 Caucasian) who are enrollees in a study of musculoskeletal conditions at the mid-life. Assignment of OAK was based on Kellgren-Lawrence (K-L) scores of 2 or more on radiographs. Prevalent OAK was based on the baseline (1996) score while the classification of incident OAK was based on a score of 2 or greater at the follow-up examination 2.5 years later amongst those with a baseline K-L scores of 0 or 1. RESULTS At baseline, the prevalence of radiographic OAK was 12% in participants who were aged 27-53 years and 18% in the subgroup of women aged 40-53 years. The mean C-RP value was 2.31 mg/L, with values ranging from below detection (0.3 mg/L) to 47.4 mg/L. Higher C-RP concentrations were associated with both prevalent and incident OAK (P < 0.0001, and P < 0.0001, respectively). For each K-L score increase from 0 to 3, there was a significantly higher mean C-RP value. Compared to women without incident OAK, women who developed OAK in the 2.5-year follow-up had significantly higher baseline C-RP concentrations. Women with bilateral OAK had higher C-RP concentrations than women with unilateral OAK (6.65 mg/L +/- 0.56 vs 3.63 mg/L +/- 0.42, P < 0.007). BMI was highly correlated with C-RP (r = 0.58) and obesity was an effect modifier with respect to OAK and C-RP concentrations. When stratified according presence or absence of OAK and obesity (BMI > 30 kg/m2), mean C-RP values were: obesity and OAK, 6.3 +/- 0.4 mg/L; obesity but not OAK, 4.3 mg/L +/- 0.2; no obesity but OAK, 1.7 mg/L +/- 0.8; and neither obesity nor OAK, 1.3 mg/L +/- 0.2 mg/L. These stratum means were significantly different from each other, indicating a higher C-RP with OAK after accounting for obesity. CONCLUSION C-RP, as a measure of an acute phase response and inflammation, is highly associated with OAK; however, its high correlation with obesity limits its utility as an exclusive marker for OAK.

[1]  E. Vignon,et al.  Increased serum C-reactive protein levels by immunonephelometry in patients with rapidly destructive hip osteoarthritis. , 1998, Revue du rhumatisme.

[2]  J. Dingle,et al.  The role of cytokines in arthritic diseases: in vitro and in vivo measurements of cartilage degradation. , 1987, International journal of tissue reactions.

[3]  E. Martı́n-Mola,et al.  Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. , 1997, The Journal of rheumatology.

[4]  T. Kikuchi,et al.  Production of cytokines by chondrocytes and its role in proteoglycan degradation. , 1991, The Journal of rheumatology. Supplement.

[5]  M. Sowers,et al.  Radiographically defined osteoarthritis of the hand and knee in young and middle-aged African American and Caucasian women. , 2000, Osteoarthritis and cartilage.

[6]  S. Krane,et al.  Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. , 1979, The Journal of clinical investigation.

[7]  S. Ricard-Blum,et al.  Type IX collagen is a potent inducer of PGE2 and interleukin 1 production by human monocyte macrophages , 1986, FEBS letters.

[8]  E. Thonar,et al.  Markers of cartilage and synovial metabolism in joint fluid and serum of patients with chondromalacia of the patella. , 1998, Osteoarthritis and cartilage.

[9]  K. Brandt,et al.  Synovial inflammation in patients with early osteoarthritis of the knee. , 1990, The Journal of rheumatology.

[10]  R. Cooper,et al.  Relationships between local inflammation, interleukin‐6 concentration and the acute phase protein response in arthritis patients , 1991, European journal of clinical investigation.

[11]  P. Dieppe,et al.  Elevated serum C-reactive protein levels in osteoarthritis. , 1997, British journal of rheumatology.

[12]  S. Goodman,et al.  Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids. , 1984, Clinical and experimental immunology.

[13]  S. Crawford,et al.  Design, survey sampling and recruitment methods of SWAN: A multi-center, multi-ethnic, community-based cohort study of women and the menopausal transition , 2000 .

[14]  J. Sipe Acute-phase proteins in osteoarthritis. , 1995, Seminars in arthritis and rheumatism.

[15]  M. Suthanthiran,et al.  Transforming growth factor-β1 hyperexpression in African American end-stage renal disease patients , 1998 .

[16]  G. Ramadori,et al.  Interleukin 6, the third mediator of acute‐phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 β and tumor necrosis factor‐α , 1988 .

[17]  S. Krane,et al.  Stimulation of procollagenase synthesis in human rheumatoid synovial fibroblasts by mononuclear cell factor/interleukin 1 , 1985, FEBS letters.

[18]  P. Sehgal,et al.  Induction of β 2-interferon by tumor necrosis factor: A homeostatic mechanism in the control of cell proliferation , 1986, Cell.

[19]  J. Pelletier,et al.  Neutral proteases in human osteoarthritic synovium. , 1986, Arthritis and rheumatism.

[20]  H. Schumacher,et al.  Effect of a nonsteroidal antiinflammatory drug on synovial fluid in osteoarthritis. , 1996, The Journal of rheumatology.

[21]  P. Dieppe,et al.  Synovial fluid concentration of five different cytokines in rheumatic diseases. , 1990, Annals of the rheumatic diseases.

[22]  J. Pelletier,et al.  Are cytokines involved in osteoarthritic pathophysiology? , 1991, Seminars in arthritis and rheumatism.

[23]  J. Pujol,et al.  The role of cytokines in the development of osteoarthritis. , 1990, Scandinavian journal of rheumatology. Supplement.

[24]  M. Pepys,et al.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. , 1983, Advances in immunology.

[25]  K. Maurer Basic data on arthritis knee, hip, and sacroiliac joints in adults ages 25-74 years. , 1979, Vital and health statistics. Series 11, Data from the National Health Survey.

[26]  J. Vilček,et al.  Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. , 1991, The Journal of biological chemistry.

[27]  G. Firestein,et al.  Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. , 1990, The Journal of clinical investigation.

[28]  J. Kelsey,et al.  Menopause : biology and pathobiology , 2000 .

[29]  W. Fiers,et al.  Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. , 1993, Immunobiology.

[30]  In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility , 1998, Rheumatology International.

[31]  I. Kushner,et al.  Monokines regulate glycosylation of acute-phase proteins , 1987, The Journal of experimental medicine.

[32]  P. Hart,et al.  Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. , 1988, The Journal of rheumatology.

[33]  A. Mackiewicz,et al.  Affinity electrophoresis for studies of mechanisms regulating glycosylation of plasma proteins , 1989, Electrophoresis.

[34]  P. Guerne,et al.  Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. , 1989, The Journal of clinical investigation.

[35]  James D. Kang,et al.  Herniated Cervical Intervertebral Discs Spontaneously Produce Matrix Metalloproteinases, Nitric Oxide, Interleukin‐6, and Prostaglandin E2 , 1995, Spine.

[36]  C. Mold,et al.  C-reactive protein and the acute phase response. , 1982, Advances in internal medicine.

[37]  C. Dinarello,et al.  Isolation of an interleukin-1-like factor from human joint effusions. , 1983, Arthritis and rheumatism.

[38]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[39]  J. Schölmerich,et al.  Interleukins and their antagonists but not TNF and its receptors are released in post‐ERP pancreatitis , 1998, European journal of gastroenterology & hepatology.

[40]  T. Spector,et al.  Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. , 1997, Arthritis and rheumatism.

[41]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[42]  M. Hochberg,et al.  Why does osteoarthritis of the knee hurt--sometimes? , 1997, British journal of rheumatology.

[43]  F. Wolfe The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. , 1997, The Journal of rheumatology.

[44]  J. Lawrence,et al.  Osteo-Arthrosis: Prevalence in the Population and Relationship between Symptoms and X-ray Changes , 1966, Annals of the rheumatic diseases.

[45]  L. Kazis,et al.  The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. , 1987, Arthritis and rheumatism.

[46]  D. Goldenberg,et al.  Inflammatory synovitis in degenerative joint disease. , 1982, The Journal of rheumatology.

[47]  J. S. Lawrence,et al.  The Epidemiology of Chronic Rheumatism , 1964 .